drugset / Trial / NCT02556736

AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

NCT02556736 ↗

Phase 1/2 Completed 14 enrolled AbbVie
Non-randomizedSequentialOpen-labelTreatment

Summary

All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.

Timeline

Start
2015-12-14
Primary completion
2020-06-01
Completion
2024-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject RST-001 Gene therapy (AAV / viral vector) — Intravitreal

Indications